Pfizer: Xeljanz Study in Juvenile Idiopathic Arthritis Met Primary Endpoint
November 12 2019 - 7:29AM
Dow Jones News
By Colin Kellaher
Pfizer Inc. (PFE) Tuesday said a phase 3 investigational study
of Xeljanz in children and adolescents with juvenile idiopathic
arthritis met its primary endpoint.
The New York drug maker said the occurrence of disease flare in
patients with polyarticular juvenile idiopathic arthritis treated
with Xeljanz was significantly lower than patients treated with
placebo at week 44.
Pfizer said it plans to file for U.S. Food and Drug
Administration approval of Xeljanz in juvenile idiopathic arthritis
in 2020.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 12, 2019 07:14 ET (12:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024
